UK's Craneware H1 revenue up 6% on sustained demand in core markets

Craneware

20/01/2026 07:13

Overview

Healthcare financial solutions firm's H1 FY26 revenue grew 6% to c.$106 mln

Adjusted EBITDA for H1 FY26 rose to c.$33.4 mln, reflecting strategic execution

Company navigated economic challenges with strong customer relationships and strategic execution

Outlook

Craneware expects double-digit growth for the year ending June 2026

Company sees favorable market conditions supporting sustainable expansion

Craneware highlights strong balance sheet and recurring revenue as growth foundations

Result Drivers

STRATEGIC PRIORITIES - Co attributes revenue and EBITDA growth to execution of strategic priorities and sustained demand in core markets

HRSA PILOT IMPACT - Temporary halt of HRSA Rebate Model Pilot affected revenue growth, but co launched a viable Rebate solution

COST MANAGEMENT - Co maintained momentum through investment in innovation, operational efficiency, and disciplined cost management

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
H1 Adjusted EBITDA
$33.40 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the software peer group is "buy."

Wall Street's median 12-month price target for Craneware PLC is GBp2,885.50, about 53.1% above its January 19 closing price of GBp1,885.00

The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 26 three months ago

Press Release: ID:nRST5109Pa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)